Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective: To examine the conditions necessary to make screening for microalbuminuria in patients with insulin dependent diabetes mellitus cost effective. Design: This economic evaluation compared two strategies designed to prevent the development of end stage renal disease in patients with insulin dependent diabetes with disease for five years. Strategy A, screening for microalbuminuria as currently recommended, was compared with strategy B, a protocol in which patients were screened for hypertension and macroproteinuria. Intervention: Patients identified in both strategies were treated with an angiotensin converting enzyme inhibitor Setting: Computer simulation Main outcome measures: Strategy costs and quality adjusted life years (QALYs). Results: The model predicted that strategy A would produce an additional 0.00967 QALYs at a present value cost of $261.53 (1990 US$) per patient (or an incremental cost/QALY of $27041.69) over strategy B. The incremental cost/QALY for strategy A over B was sensitive to several variables. If the positive predictive value of screening for microalbuminuria (impact of false label and unnecessary treatment) is <0.72, the effect of treatment to delay progression from microalbuminuria to macroproteinuria is <1.6 years, the cumulative incidence of diabetic nephropathy falls to <20%, or >64% of patients demonstrate hypertension at the onset of microalbuminuria, then the incremental costs/QALY will exceed $75000. Conclusions: Whether microalbuminuria surveillance in this population is cost effective requires more information. Being aware of the costs, recommendation pitfalls, and gaps in our knowledge should help focus our efforts to provide cost effective care to this population
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202
Cited by
One Thousand Health-Related Quality-of-Life Estimates
Tengs, T. O., & Wallace, A. (2000) · Medical Care · doi:10.1097/00005650-200006000-00004 · Cited by 662
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
A review of the use of health status measures in economic evaluation.
Brazier, Deverill, Green, Harper, & Booth (1999) · Health Technology Assessment · doi:10.3310/hta3090 · Cited by 413
Handling uncertainty when performing economic evaluation of healthcare interventions.
Briggs, & Gray (1999) · Health Technology Assessment · doi:10.3310/hta3020 · Cited by 387
Screening for Proteinuria in US Adults: A Cost-effectiveness Analysis
Boulware, L. E., Jaar, B. G., Tarver-Carr, M. E., Brancati, F. L., & Powe, N. R. (2003) · JAMA · doi:10.1001/jama.290.23.3101 · Cited by 381
Metadata
- Authors
- Kiberd, B. A., & Jindal, K. K.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1995-12-16
- Volume
- 311
- Issue
- 7020
- Pages
- 1595-1599
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1974872316
- Cited by
- 102
- References
- 2
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. https://app.cochat.ai/papers/10.1136/bmj.311.7020.1595
- The paper
- Kiberd, B. A., & Jindal, K. K. (1995). Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ. https://doi.org/10.1136/bmj.311.7020.1595
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.